US Foods

Vieworks Wins FDA Approval for Its Newest VIVIX-S F series

Retrieved on: 
Friday, August 5, 2022 - 2:00pm
FDA, NFC, Multimedia, View, Fast, OLED, US Foods, Food

ANYANG, South Korea, Aug. 5, 2022 /PRNewswire/ -- Vieworks, a leading digital X-ray imaging solution provider based in South Korea, noted that its newest VIVIX-S F series has been authorized by the US Food and Drug Administration (FDA) last July.

Key Points: 
  • ANYANG, South Korea, Aug. 5, 2022 /PRNewswire/ -- Vieworks, a leading digital X-ray imaging solution provider based in South Korea, noted that its newest VIVIX-S F series has been authorized by the US Food and Drug Administration (FDA) last July.
  • Regulatory clearance from the FDA will allow Vieworks to commercialize its new VIVIX-S F series, which is Vieworks' premium static X-ray DR flat panel detectors equipped with advanced technology and cutting-edge hardware design.
  • The cassette-sized DR detectors are offered in 3 sizes 25x30cm (VIVIX-S 2530FW), 36x43cm (VIVIX-S 3643FW), and 43x43cm (VIVIX-S 4343FW).
  • Advanced image processing technology (VXvue, Software-based Scatter Correction)
    Excellent durability (1.5m drop tested, 400kg load limit)
    Long lasting battery life (16 hours with two batteries, hot-swap mode)
    Easy usage with user-friendly functions (Fast and convenient detector sharing by NFC, OLED status screen)
    View original content to download multimedia: https://www.prnewswire.com/news-releases/vieworks-wins-fda-approval-for-...

Vieworks Wins FDA Approval for Its Newest VIVIX-S F series

Retrieved on: 
Friday, August 5, 2022 - 2:00pm
FDA, NFC, Fast, OLED, US Foods, Food

ANYANG, South Korea, Aug. 5, 2022 /PRNewswire/ -- Vieworks, a leading digital X-ray imaging solution provider based in South Korea, noted that its newest VIVIX-S F series has been authorized by the US Food and Drug Administration (FDA) last July.

Key Points: 
  • ANYANG, South Korea, Aug. 5, 2022 /PRNewswire/ -- Vieworks, a leading digital X-ray imaging solution provider based in South Korea, noted that its newest VIVIX-S F series has been authorized by the US Food and Drug Administration (FDA) last July.
  • Regulatory clearance from the FDA will allow Vieworks to commercialize its new VIVIX-S F series, which is Vieworks' premium static X-ray DR flat panel detectors equipped with advanced technology and cutting-edge hardware design.
  • The cassette-sized DR detectors are offered in 3 sizes 25x30cm (VIVIX-S 2530FW), 36x43cm (VIVIX-S 3643FW), and 43x43cm (VIVIX-S 4343FW).
  • Advanced image processing technology (VXvue, Software-based Scatter Correction)
    Excellent durability (1.5m drop tested, 400kg load limit)
    Long lasting battery life (16 hours with two batteries, hot-swap mode)
    Easy usage with user-friendly functions (Fast and convenient detector sharing by NFC, OLED status screen)

Stellar Solar Wins Best Solar Power Company in the 2022 San Diego Union Tribune Readers Poll - Marking The Sixth Year in a Row

Retrieved on: 
Friday, August 5, 2022 - 1:04pm
Stellar, Adoption, US Foods, Better Business Bureau, The San Diego Union-Tribune, Salk Institute for Biological Studies, School, SAN, EV, Operation, Union, News, Cedars-Sinai Medical Center, Organic, Organization, Renewable energy

SAN DIEGO, Aug. 5, 2022 /PRNewswire/ -- Stellar Solar, one of San Diego's most experienced solar and battery storage installers since 1998, has won the San Diego Union Tribune Readers Poll in the category of Best Solar Company again in 2022, making it a record six consecutive years winning the award.  Their victory in 2022 adds to wins in 2011, 2013, 2014, 2015, 2017, 2018, 2019, 2020 and 2021. The winning streak extends their record in the category of Best Solar Panel Company and is a direct reflection on the satisfaction of their 15,000 + residential and commercial customers. The win further solidifies Stellar Solar as a preferred choice for home and business owners who are looking to install solar, battery storage, and EV connectivity.

Key Points: 
  • Their victory in 2022 adds to wins in 2011, 2013, 2014, 2015, 2017, 2018, 2019, 2020 and 2021.
  • The win further solidifies Stellar Solar as a preferred choice for home and business owners who are looking to install solar, battery storage, and EV connectivity.
  • Stellar Solar offers quick, easy, no-pressure virtual residential solar quotes for homeowners interested in solar.
  • Readers of the Union Tribune have voted them best solar panel company again in 2022, marking the sixth year in a row and tenth time in twelve years winning the award.

Evio & Aetion Partner to Deliver Real-World Evidence (RWE) Across the Pharmacy Value Chain

Retrieved on: 
Thursday, August 4, 2022 - 2:00pm
Multimedia, Pharmacy, Blue Cross Blue Shield Association, CEO, Senior, Technology, Clinical trial, RWE, Health, Patient, Epidemiology, Inform, Facilitation, View, Data analysis, Safety, AEP, Protocol, Physician, Health information management, US Foods, Food, Pharmaceutical industry, Medical device, Medical imaging, Aetion

DENVER and NEW YORK, Aug. 4, 2022 /PRNewswire/ -- Evio, an independent pharmacy solutions company dedicated to ensuring every patient receives the right medications in a simple and affordable way, today announced a new collaboration with Aetion, a global real-world evidence (RWE) technology and analytics provider, to drive increased use of RWE in pharmacy solutions and decision-making. 

Key Points: 
  • The agreement enables Evio to leverage the Aetion Evidence Platform (AEP), which is scientifically validated software that transforms real-world data into transparent, reliable, and replicable RWE and patient insights.
  • "Today, patients are steered towards medications based on their preferred status on a formulary that is typically driven by rebates and pay-to-play.
  • We are pleased to work with Aetion, the recognized leader in this space, as part of our efforts to change the paradigm of the pharmacy value chain."
  • The Aetion Evidence Platform analyzes data from the real world to produce transparent, rapid, and scientifically validated answers on safety, effectiveness, and value.

XORTX Announces Pre-Phase 3 Meeting Date with US Food and Drug Administration

Retrieved on: 
Thursday, August 4, 2022 - 12:00pm
Kidney disease, No, Diagnosis, Security (finance), COVID-19, Marketing, Quality of life, Xanthine oxidase, Cyst, Analysis, Diabetic nephropathy, ADPKD, TSX Venture Exchange, Food, Patient, Company, NASDAQ, Chronic pain, GMP, Plasma protein binding, NDA, U.S. Securities and Exchange Commission, Unitary state, FDA, Polycystic kidney disease, Oxipurinol, News, Research, US Foods, Uric acid, Form, Health, GLOBE, Incidence, Therapy, Autosome, Health Canada, Coronavirus, International, Fibrosis, SEC, File, Pharmaceutical industry, Medical device, Nasdaq

In advance of this meeting, XORTX has submitted a Pre-Phase-3 Briefing Package to the FDA on Thursday, July 28, 2022.

Key Points: 
  • In advance of this meeting, XORTX has submitted a Pre-Phase-3 Briefing Package to the FDA on Thursday, July 28, 2022.
  • The Company has achieved successful regulatory filings with the FDA and Health Canada and has commenced its OXY-XRX-101 bridging pharmacokinetics study.
  • These important milestones have well positioned XORTX for this pre-Phase 3 meeting with the FDA.
  • The Pre-Phase 3 Briefing Package provides an up-to-date summary of the extensive work completed for the XRx-008 program and this type B meeting.

COMPASS Pathways plc announces second quarter 2022 financial results and business highlights

Retrieved on: 
Thursday, August 4, 2022 - 12:00pm
Phase II, Post-traumatic stress disorder, CMPS, Goldsmith, TRD, Senior, Innovation, ASD, Clinical trial, Mental Health Research Institute (Melbourne), COMPASS, Autism, III, Investor, Columbia University Irving Medical Center, Patient, Food, Mental health, Review, II, IIB, Nasdaq, FDA, University College London Hospitals NHS Foundation Trust, Mount Sinai Hospital, Policy, Institute, South London and Maudsley NHS Foundation Trust, Research, Institute of Psychiatry, Psychology and Neuroscience, US Foods, Otsuka Pharmaceutical, Sheppard and Enoch Pratt Hospital, Anorexia nervosa, Psilocybin, Principal investigator, Slam, R, CEO, KOL, PTSD, Webcast, G&A, UC San Diego School of Medicine, Leadership, Psychology, University, Center, Partnership, King's College London, Pharmaceutical industry, Online gambling, Video game

COMPASS Pathways plc (Nasdaq: CMPS) (COMPASS), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health, today reported its financial results for the second quarter 2022 and gave an update on recent progress across its business.

Key Points: 
  • COMPASS Pathways plc (Nasdaq: CMPS) (COMPASS), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health, today reported its financial results for the second quarter 2022 and gave an update on recent progress across its business.
  • The COMPASS Pathways management team will host a conference call at 8.00am ET (13.00 UK) on 4 August 2022.
  • A live webcast of the call will be available on COMPASS Pathways website at: Second Quarter 2022 Financial Results .
  • COMPASS Pathways plc (Nasdaq: CMPS) is a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health.

Bioventus Receives FDA 510(k) Clearance for SonaStar Elite  

Retrieved on: 
Wednesday, August 3, 2022 - 12:00pm
Innovation, Twitter, Projection, U.S. Securities and Exchange Commission, Neurosurgery, Nasdaq, Terminology, LinkedIn, Malignancy, Risk, Physician, US Foods, SEC, Security (finance), History, Patient, Failure, SSE, Neoplasm, GLOBE, Forward-looking statement, Review, Research, Food, FDA, COVID-19, Investment, Evidence-based medicine, Company, Surgeon, NEXUS, Government, Medical imaging

DURHAM, N.C., Aug. 03, 2022 (GLOBE NEWSWIRE) --  Bioventus Inc. (Nasdaq: BVS) (“Bioventus” or the “Company”), a global leader in innovations for active healing, announced the US Food and Drug Administration (FDA) has granted 510(k) clearance for the company’s neXus® SonaStar Elite® handpiece. The SonaStar Elite (SSE) handpiece is powered by the neXus Ultrasonic Surgical Aspirator System, a next generation integrated ultrasonic surgical platform driven by a proprietary digital algorithm resulting in more versatility and control. The neXus system combines all the features of soft and hard (including bone) tissue removal into a single fully integrated platform capable of operating at multiple frequencies, including the newly approved 36 kHz SonaStar Elite Handpiece.

Key Points: 
  • DURHAM, N.C., Aug. 03, 2022 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS) (Bioventus or the Company), a global leader in innovations for active healing, announced the US Food and Drug Administration (FDA) has granted 510(k) clearance for the companys neXus SonaStar Elite handpiece.
  • The SonaStar Elite (SSE) handpiece is powered by the neXus Ultrasonic Surgical Aspirator System, a next generation integrated ultrasonic surgical platform driven by a proprietary digital algorithm resulting in more versatility and control.
  • "The SonaStar Elite handpiece is the latest innovation in our neXus ultrasonic surgical pipeline," commented Andrew Hosmer, general manager, Surgical Solutions, at Bioventus.
  • Bioventus and the Bioventus logo are registered trademarks of Bioventus LLC.

Zhaoke Ophthalmology Completed Patient Enrollments for the Phase III Clinical Trials of the Myopia Progression Treatment Drug NVK002

Retrieved on: 
Wednesday, August 3, 2022 - 2:16am
World, Motherboard, Atropine, Ageing, State Council, Parent, Eye, Safety, Episode I, Sun, Ministry, Director, Company, Fudan University, S. D. Warren Co. v. Maine Board of Environmental Protection, Eye and ENT Hospital of Fudan University, Control, Research, World Health Organization, Technology, US Foods, Growth, List of education ministries, Education, Business, Adolescence, Food, SEHK, CEO, Board, Ophthalmology, Achievement, FDA, Benjamin, National Health Planning and Resources Development Act, Cover My Eyes (Pain and Heaven), Approximation error, Beijing Tongren Hospital, NDA, CIC, The Company, Hospital, Principal, Hong Kong Stock Exchange, Patient, Overalls, Pharmaceutical industry, Vaccine, Medical imaging, Myopia

The primary objective of the China CHAMP and Mini-CHAMP trials is to evaluate the efficacy and safety of NVK002 for the treatment of myopia progression in children and adolescents.

Key Points: 
  • The primary objective of the China CHAMP and Mini-CHAMP trials is to evaluate the efficacy and safety of NVK002 for the treatment of myopia progression in children and adolescents.
  • These early completions of patient recruitment across both trials, gives the company a strong headstart in moving towards its goal to lead the market in launching a myopia progression treatment drug.
  • Following this, a New Drug Application ("NDA") submission to the US Food and Drug Administration (the "FDA") is expected in 2023.
  • Dr. Li Xiaoyi (Benjamin), Chairman of the Board of Directors, Executive Director and CEO of Zhaoke Ophthalmology, said, "The early completion of the patient recruitment of NVK002's Phase III clinical trials marks another huge and exciting milestone for Zhaoke Ophthalmology.

COMPASS Pathways Announces Grant of Inducement Award for Newly Appointed Chief Executive Officer Pursuant to Nasdaq Listing Rule 5635(c)(4)

Retrieved on: 
Tuesday, August 2, 2022 - 9:05pm
GLOBE, TRD, Food, American depositary receipt, CMPS, Director, Clinical trial, Mental health, US Foods, FDA, Company, COMPASS, Nasdaq, Compensation, Employment, IIB, Medicine

In accordance with NASDAQ Listing Rule 5635(c)(4), the non-qualified share option award was approved by the Compensation and Leadership Development Committee of COMPASSs Board of Directors and made as a material inducement to Kabirs entry into employment with COMPASS as its new chief executive officer.

Key Points: 
  • In accordance with NASDAQ Listing Rule 5635(c)(4), the non-qualified share option award was approved by the Compensation and Leadership Development Committee of COMPASSs Board of Directors and made as a material inducement to Kabirs entry into employment with COMPASS as its new chief executive officer.
  • COMPASS Pathways plc (Nasdaq: CMPS) is a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health.
  • COMPASS is headquartered in London, UK, with offices in New York and San Francisco in the US.
  • These forward-looking statements are based on COMPASSs current expectations and speak only as of the date hereof.

XR Immersive Tech Announces SynthesisVR Android Platform

Retrieved on: 
Tuesday, August 2, 2022 - 12:45pm
Metaverse, Augmented reality, Immersion, GLOBE, Oculus Quest 2, Vive, Capital One, Industry, Food, Intel, Reality–virtuality continuum, Sairento VR, Computing, Partnership, Virtual reality, Meta, Android, Scotiabank, Allegiant Air, News, Computing platform, US Foods, Company, AR, Online social entertainment, COVID, CSE, VR, Perception, Mark (given name), Growth, Mobile phone, Video game console, Information technology, Bayer

VANCOUVER, British Columbia, Aug. 02, 2022 (GLOBE NEWSWIRE) -- XR Immersive Tech Inc. (Immersive Tech, or the Company) (CSE:VRAR) (FSE:79W) (OTCQB: FNTTF) is pleased to announce that our SynthesisVR Android Platform has officially launched and is currently available to the Companys operator network worldwide.

Key Points: 
  • VANCOUVER, British Columbia, Aug. 02, 2022 (GLOBE NEWSWIRE) -- XR Immersive Tech Inc. (Immersive Tech, or the Company) (CSE:VRAR) (FSE:79W) (OTCQB: FNTTF) is pleased to announce that our SynthesisVR Android Platform has officially launched and is currently available to the Companys operator network worldwide.
  • After many months of testing and feedback from our partners we are pleased to announce that the SynthesisVR Android Platform is now officially live.
  • To learn more about the SynthesisVR Android Platform or to start a free trial please visit the SynthesisVR website to get in touch.
  • ABOUT XR IMMERSIVE TECH INC.
    XR Immersive Tech is building the industry's premier location-based Metaverse Platform.